Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | LIPE | Q05469 | 10/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | VNN1 | O95497 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5530111 | 0.86 | OPRM1 (0.56) | LMNALIPEHRH3 | |
| SCHEMBL9607063 | 0.85 | LMNA (0.53) | LMNALIPEMAPTVNN1HRH3 | |
| SCHEMBL30125067 | 0.85 | L3MBTL1 (0.47) | LMNALIPERAB9AMAPTHPGD | |
| SCHEMBL26835764 | 0.85 | L3MBTL1 (0.47) | LMNALIPERAB9AMAPTHPGD | |
| SCHEMBL13279297 | 0.84 | PDE4B (0.54) | LMNALIPEMAPTHPGDVNN1 | |
| SCHEMBL27295620 | 0.84 | HRH3 (0.58) | LMNALIPERAB9AMAPTHPGD | |
| SCHEMBL29815410 | 0.84 | HRH3 (0.58) | LMNALIPERAB9AMAPTHPGD | |
| SCHEMBL25172927 | 0.82 | MAPT (0.52) | LMNALIPERAB9AMAPTHPGD | |
| SCHEMBL29593315 | 0.82 | KDM4E (0.56) | LMNALIPERAB9AMAPTHPGD | |
| SCHEMBL19778853 | 0.82 | KDM4E (0.56) | LMNALIPERAB9AMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10799494-B2 | Combination of respiratory electron transport chain inhibitors with a cytochrome bd inhibitor | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2020-10-13 | — | — | US | disclosed |
| US-20190151305-A1 | COMBINATION PRODUCT | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2019-05-23 | — | — | US | disclosed |
| EP-3389659-A1 | COMBINATION PRODUCT | Liverpool School of Tropical Medicine (GB) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017103615-A1 | COMBINATION PRODUCT | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10799494-B2 | Combination of respiratory electron transport chain inhibitors with a cytochrome bd inhibitor | NDUFB7, NDUFB3, NDUFB5 | LMNA 3846/4885LIPE 4702/4885RAB9A 1518/4885 |
| US-20190151305-A1 | COMBINATION PRODUCT | NDUFB5, NDUFB7, NDUFB10 | LMNA 3756/4885LIPE 4531/4885RAB9A 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.